Clinical Trial Update: Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial in mesothelioma evaluating ADI-PEG 20 with pemetrexed and cisplatin completed, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)
• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Polaris Group | Conditions: Mesothelioma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-10-04